Health
COVID: new antibody treatment could offer up to 18 months’ protection against severe disease – The Conversation UK
AstraZeneca’s durable monoclonal antibody treatment has shown promise in phase 3 clinical trials.
A new treatment could soon help protect people from developing severe COVID. AstraZeneca has just released results from a phase 3 clinical trial the final stage of testing before a drug is authorised that suggest its new COVID treatment, AZD7442, is effective…
Continue Reading
-
Noosa News23 hours agoGippsland vegetable farm accused of underpaying migrant workers
-
General24 hours agoFour escape injury after jumping from three-storey unit on fire in Newcastle
-
General16 hours agoMan refused bail charged with depicting Adolf Hitler and Nazi symbols on boat
-
Noosa News13 hours agoAlternative pathways to university explained